Approaching Zero: How West Africa is Crushing the Ebola Epidemic

The West African Ebola outbreak is finally starting to approach manageable levels, after nearly 18 excruciating months and over 11,000 lost lives. Here’s what the current situation on the ground looks like and how the battle against Ebola finally might be won.

This is the largest and longest Ebola outbreak in human history. At its peak, there were 950 confirmed cases each week, prompting fears of a global pandemic. Officials have reported 28,421 confirmed, probable, and suspected cases in Guinea, Liberia, and Sierra Leone. Of these, some 11,300 people have died — a fatality rate of 40%. A total of 881 healthcare workers have been infected; of those, 513 died.

The effects will be felt for years to come. The loss of so many medical personnel is expected to have downstream effects on the health system of affected West African countries, including a sharp rise in maternal mortality to the tune of an additional 4,022 deaths each year for the foreseeable future. Moreover, the ability of healthcare workers to deal with other major diseases, like Malaria and Lassa (another hemorrhagic fever), was severely curtailed during the epidemic.

Link to full article on Gizmodo

Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors — Preliminary Report

LONDON — Doctors have found that Ebola can linger in some male survivors for up to nine months but aren’t sure if that means they might still be infectious, according to new research.

In a study of 93 men in Sierra Leone, scientists found the Ebola virus in semen samples from about half of them. The risk seemed to decline over time. Ebola was detected in all nine men tested at two to three months after their illness began but in only 11 of the 43 survivors tested at seven to nine months.

Link to Mashable

 

Link to NE Journal of Medicine Article

Ebola Drug Aids Some in a Study in West Africa

or the first time, a drug is showing promising signs of effectiveness in Ebola patients participating in a study. The medicine, which interferes with the virus’s ability to copy itself, seems to have halved mortality — to 15 percent, from 30 percent — in patients with low to moderate levels of Ebola in their blood, researchers have found. It had no effect in patients with more virus in their blood, who are more likely to die.

The drug, approved as an influenza treatment in Japan last year, was generally well tolerated.

“The results are encouraging in a certain phase of the disease,” Dr. Sakoba Keita, director of disease control for the Guinean Ministry of Health, said in a telephone interview. The drug is being tested in Guinea, one of the three West African countries most affected by the Ebola crisis.

Full Story